Characterization and management of gastrointestinal (Gi) adverse events (Aes) with zanidatamab + chemotherapy (Ct) ± tislelizumab in first-line (1l) HER2-positive (Her2+) locally advanced or metastatic gastroesophageal adenocarcinoma (Mgea): Analysis from HERIZON-GEA-01
Elimova, E., Rha, S. Y., Shitara, K., Liu, T., Tabernero, J., Lee, K.-W., Schenker, M., Tebbutt, N. C., Ajani, J. … Read More
